AZD-1222/tozinameran: Leukocytoclastic vasculitis and injection site pain : 2 case reports.

Two case reports describe patients who developed leukocytoclastic vasculitis (LCV) and injection site pain after receiving the AZD-1222 (Oxford/AstraZeneca) or tozinameran (Pfizer-BioNTech) COVID-19 vaccines. The first patient, a 59-year-old man, experienced rashes, swelling, and injection site pain after the AZD-1222 vaccine. He was diagnosed with LCV and treated with steroids, which resolved his skin lesions. The second patient, an 87-year-old woman, developed skin lesions and injection site pain after the tozinameran vaccine. She was also diagnosed with LCV and treated with prednisone and colchicine, resulting in significant improvement in her skin lesions. Both patients declined to receive the second dose of the vaccine. [Extracted from the article]